Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REC601
- Development stage
- Unknown
- Lead developer
- Recbio
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
REC601 is a recombinant bivalent human papillomavirus (HPV) vaccine developed by Jiangsu Recbio Technology Co., Ltd., targeting HPV types 16 and 18, which are responsible for the majority of cervical cancers. It utilizes recombinant protein technology with a self-developed novel adjuvant similar to AS04 to elicit strong neutralizing antibody responses against these high-risk HPV types. The vaccine is designed for prevention of HPV-related diseases, including cervical cancer, and has completed Phase I clinical trials, demonstrating favorable safety and immunogenicity profiles.
- Other names
- Recombinant HPV bivalent vaccine (Types 16/18)
02
Targets
HPV16 L1HPV18 L1
Beyond the preview
Go deeper on REC601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REC601.